ReviewLife (Basel, Switzerland)2026
The Ocular Signature of TBI: A Narrative Review of Structural Changes and Potential Candidate Biomarkers.
Review in Life (Basel, Switzerland), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundTraumatic brain injury (TBI) damages brain tissues and affects the ocular system. Ocular manifestations such as orbital fractures, ocular surface disease, photosensitivity, impaired pupillary response, and retinal damage often co-occur with TBI. Despite established diagnostic criteria, a gap remains, particularly in detection, monitoring, and recovery prediction. Since ocular manifestations co-occur with TBI, they may offer non-invasive means to address this gap. Accordingly, this review evaluates whether TBI-associated ocular manifestations can serve as biomarkers for TBI detection, monitoring, and recovery.
methodsA literature search was conducted across three databases for studies that address ocular manifestations of TBI listed above.
resultsOrbital fractures occur in 69%, matching TBI severity. Occult fractures may indicate unseen mild TBI on advanced neuroimaging. Dry eye disease prevalence is inconsistent (15 and 37%). Tear film proteomics show altered inflammatory and repair proteins, though this area remains understudied. Vitreous total tau and neurofilament light chain correlate with brain levels in chronic traumatic encephalopathy. Photosensitivity affects approximately 50% of acute TBI and declines to 14% after three months. NPi-200 pupillometer shows high specificity in triaging acute injury but with low sensitivity. PLR-3000 pupillometer and smartphone applications require further validation. Retinal imaging shows biphasic thickening then progressive thinning, modulated by sex, severity and duration.
conclusionsNo single ocular biomarker fulfills all roles. Instead, different markers map into distinct stages of the clinical course. Future research should prioritize molecular markers in the tear film, combined with changes in corneal nerves across different TBI severities.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.